These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28546528)

  • 41. Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902).
    Ozaki S; Hata H; Abe M; Saitoh T; Hanamura I; Yano H; Sunami K; Kosugi H; Sawamura M; Nakazato T; Masunari T; Mori M; Takagi T; Murakami H; Shimizu K
    Ann Hematol; 2016 May; 95(6):921-9. PubMed ID: 27044390
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
    Richardson PG; Wolf J; Jakubowiak A; Zonder J; Lonial S; Irwin D; Densmore J; Krishnan A; Raje N; Bar M; Martin T; Schlossman R; Ghobrial IM; Munshi N; Laubach J; Allerton J; Hideshima T; Colson K; Poradosu E; Gardner L; Sportelli P; Anderson KC
    J Clin Oncol; 2011 Nov; 29(32):4243-9. PubMed ID: 21990396
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
    Knopf KB; Duh MS; Lafeuille MH; Gravel J; Lefebvre P; Niculescu L; Ba-Mancini A; Ma E; Shi H; Comenzo RL
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):380-8. PubMed ID: 25023616
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
    Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ;
    Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
    Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
    Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical effects of CD33 and MPC-1 on the prognosis of multiple myeloma treated with bortezomib.
    Oka S; Ono K; Nohgawa M
    Leuk Lymphoma; 2019 Sep; 60(9):2152-2157. PubMed ID: 30887866
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.
    Ludwig H; Viterbo L; Greil R; Masszi T; Spicka I; Shpilberg O; Hajek R; Dmoszynska A; Paiva B; Vidriales MB; Esteves G; Stoppa AM; Robinson D; Ricci D; Cakana A; Enny C; Feng H; van de Velde H; Harousseau JL
    J Clin Oncol; 2013 Jan; 31(2):247-55. PubMed ID: 23091109
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
    Ning YM; He K; Dagher R; Sridhara R; Farrell AT; Justice R; Pazdur R
    Oncology (Williston Park); 2007 Nov; 21(12):1503-8; discussion 1511, 1513, 1516 passim. PubMed ID: 18077994
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.
    Mai EK; Bertsch U; Dürig J; Kunz C; Haenel M; Blau IW; Munder M; Jauch A; Schurich B; Hielscher T; Merz M; Huegle-Doerr B; Seckinger A; Hose D; Hillengass J; Raab MS; Neben K; Lindemann HW; Zeis M; Gerecke C; Schmidt-Wolf IG; Weisel K; Scheid C; Salwender H; Goldschmidt H
    Leukemia; 2015 Aug; 29(8):1721-9. PubMed ID: 25787915
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.
    Moreau P; Joshua D; Chng WJ; Palumbo A; Goldschmidt H; Hájek R; Facon T; Ludwig H; Pour L; Niesvizky R; Oriol A; Rosiñol L; Suvorov A; Gaidano G; Pika T; Weisel K; Goranova-Marinova V; Gillenwater HH; Mohamed N; Aggarwal S; Feng S; Dimopoulos MA
    Leukemia; 2017 Jan; 31(1):115-122. PubMed ID: 27491641
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
    Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
    J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].
    Takeda Y; Sakaida E; Nakaseko C
    Nihon Rinsho; 2015 Jan; 73(1):130-6. PubMed ID: 25626318
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously Untreated Myeloma Patients Eligible for Transplants.
    Chen JF; Xiao LF; Zhang R; Zeng ZH; Li YX; Meng XY
    Acta Haematol; 2017; 137(4):207-208. PubMed ID: 28472803
    [No Abstract]   [Full Text] [Related]  

  • 56. [Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].
    Titos-Arcos JC; León-Villar J; de Arriba de la Fuente F; Moreno Belmonte MJ; Iranzo Fernández MD
    Farm Hosp; 2012; 36(4):275-81. PubMed ID: 22115856
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.
    Ibata S; Sato T; Kuroda H; Nagamachi Y; Iyama S; Fujimi A; Kamihara Y; Konuma Y; Yoshida M; Tatekoshi A; Hashimoto A; Horiguchi H; Ono K; Murase K; Takada K; Miyanishi K; Kobune M; Hirayama Y; Kato J
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1041-1049. PubMed ID: 27738809
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS.
    Romaniuk W; Bolkun L; Kalita J; Galar M; Bernatowicz M; Ostrowska H; Kloczko J
    Ann Hematol; 2018 Oct; 97(10):1879-1887. PubMed ID: 29946907
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
    Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.